An estimated 180,000 new cases of lung cancer will be diagnosed in the United States this
year, and lung cancer accounts for approximately 25% of all cancer deaths. The overall 5 …

An estimated 180,000 new cases of lung cancer will be diag nosed in the US this year, and
lung cancer accounts for approximately 25% of all cancer deaths. Most lung cancers are …

The primary clinical application of FDG-PET is in the evaluation of patients with lung cancer
and includes diagnosis, staging and restaging of non-small cell lung cancer. PET has a very …

Abstract 18 F-fluorodeoxyglucose (FDG) PET imaging provides physiologic and metabolic
information that characterizes lesions that are indeterminate by CT. FDG PET imaging is …

In the last hundred years, lung cancer has risen from a reportable disease to the most
common cause of death from cancer in both men and women in developed countries (1) …

Objective: Positron emission tomography (PET), when used with the intravenously
administered radiopharmaceutical F-18 fluorodeoxyglucose (FDG), has the potential to help …

Background: Accurate staging is crucial for the proper management of patients with
nonsmall cell lung cancer, especially for choosing the best treatment strategy. Different …

Imaging techniques play an essential role in the diagnosis, staging, and follow-up of patients
with lung cancer. Positron emission tomography (PET) has become an important innovation …

This review summarizes the current literature and tries to define the status of nuclear
medicine in the clinical workup of lung cancer patients. Nuclear medicine procedures and …

In the past 10 years, positron emission tomography (PET), usually with 18 F-fluoro-2-deoxy-
D-glucose (FDG), has become an important imaging modality in patients with lung cancer …